Conclusion:
Hemolytic anemia is a significant complication associated with the use
of primaquine. Therefore, screening for G6PD deficiency is essential
before initiating primaquine therapy, and heightened vigilance is
necessary even when G6PD levels are within the normal range on
screening. There is a need for clearer instructions on how to detect
signs of hemolysis.